EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 26 / No 6-7 (Juin–Juillet 2010) Med Sci (Paris), 26 6-7 (2010) 647-651 References
Free Access
Issue
Med Sci (Paris)
Volume 26, Number 6-7, Juin–Juillet 2010
Page(s) 647 - 651
Section M/S revues
DOI https://doi.org/10.1051/medsci/2010266-7647
Published online 15 June 2010
  1. Beaulieu JM, Sotnikova TD, Marion S. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005 ; 122 : 261-73. [Google Scholar]
  2. Beaulieu JM, Tirotta E, Sotnikova TD, et al. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 2007 ; 27 : 881-5. [Google Scholar]
  3. Galandrin S, Oligny-Longpré G, Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 2007 ; 28 : 423-30. [Google Scholar]
  4. Luttrell LM, Ferguson SS, Daaka Y, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999 ; 283 : 655-61. [Google Scholar]
  5. Beaulieu JM, Gainetdinov RR, Caron MG. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009 ; 49 : 327-47. [Google Scholar]
  6. Svenningsson P, Nishi A, Fisone G, et al. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 2004 ; 44 : 269-96. [Google Scholar]
  7. Woodgett JR. Judging a protein by more than its name: GSK-3. Sci STKE 2001 ; 2001 : RE12. [Google Scholar]
  8. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopaminedependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004 ; 101 : 5099-104. [Google Scholar]
  9. Gainetdinov RR, Wetsel WC, Jones SR, et al. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999 ; 283 : 397-401. [Google Scholar]
  10. Prickaerts J, Moechars D, Cryns K, et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 2006 ; 26 : 9022-9. [Google Scholar]
  11. Gould TD, Einat H, O’Donnell KC, et al. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology 2007 ; 32 : 2173-83. [Google Scholar]
  12. Beaulieu JM, Gainetdinov RR, Caron MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007 ; 28 : 166-72. [Google Scholar]
  13. Ferguson SS, Downey WE 3rd, Colapietro AM, et al. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996 ; 271 : 363-6. [Google Scholar]
  14. Lohse MJ, Benovic JL, Codina J, et al. beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 1990 ; 248 : 1547-50. [Google Scholar]
  15. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science 2005 ; 308 : 512-7. [Google Scholar]
  16. Li X, Rosborough KM, Friedman AB, et al. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 2007 ; 10 : 7-19. [Google Scholar]
  17. Li X, Zhu W, Roh MS, et al. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004 ; 29 : 1426-31. [Google Scholar]
  18. Polter A, Yang S, Zmijewska AA, et al. Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol Psychiatry 2009 ; 65 : 150-9. [Google Scholar]
  19. Beaulieu JM, Zhang X, Rodriguiz RM, et al. Role of GSK3beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 2008 ; 105 : 1333-8. [Google Scholar]
  20. Emamian ES, Hall D, Birnbaum MJ, et al. Convergent evidence for impaired AKTL-GSK3beta signaling in schizophrenia. Nat Genet 2004 ; 36 : 131-7. [Google Scholar]
  21. Alimohamad H, Rajakumar N, Seah YH, Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005 ; 57 : 533-42. [Google Scholar]
  22. Beaulieu JM. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int J Neuropsychopharmacol 2007 ; 10 : 3-6. [Google Scholar]
  23. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001 ; 41 : 789-813. [Google Scholar]
  24. Beaulieu JM, Caron MG. Looking at lithium: molecular moods and complex behaviour. Mol Interv 2008 ; 8 : 230-41. [Google Scholar]
  25. Beaulieu JM, Marion S, Rodriguiz RM, et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 2008 ; 132 : 125-36. [Google Scholar]
  26. Kovacsics CE, Gottesman II, Gould TD. Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol 2009 ; 49 : 175-98. [Google Scholar]
  27. Mao Y, Ge X, Frank CL, et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 2009 ; 136 : 1017-31. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.